Publications by authors named "A de Labriolle"

Claim this Profile
R
Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial.
Robert A Byrne, Róisín Colleran, J J Coughlan, Rajiv Jauhar, Luc Maillard, Axel De Labriolle

Circ Cardiovasc Interv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year clinical outcomes using the bioresorbable vascular scaffold: Insights from the FRANCE ABSORB registry.
Quentin Landolff, Thierry Lefèvre, Jean Fajadet, Joel Sainsous, Thibault Lhermusier, Axel De Labriolle

Arch Cardiovasc Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high-risk patients: The e-Cobra study.
Luc Maillard, Axel de Labriolle, Camille Brasselet, Benjamin Faurie, Nicolas Durel

Catheter Cardiovasc Interv· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry.
Etienne Puymirat, Julia Caudron, Philippe G Steg, Gilles Lemesle, Yves Cottin, Axel de Labriolle

Eur Heart J Acute Cardiovasc Care· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
Axel de Labriolle, Jean Philippe Doazan, Gilles Lemesle, Laurent Bonello

Curr Cardiol Rep· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis